

## Freedom of Information Request: Our Reference CTMUHB\_195\_23

### You asked:

Could you please tell me how many of the following intra-vitreous injections/implants has your Health Board administered in the four-month period from January to April 2023:

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Faricimab
- Fluocinolone acetonide
- Ranibizumab - Lucentis
- Ranibizumab – Ongavia
- Ranibizumab – Byooviz
- Ranibizumab - Ximluci

### Our response:

Please find below a table populated with data that is available to Medicines Management for the period of January 23 to April 23, as requested.

Medicine	Number Administered
Aflibercept	1687
Bevacizumab	26
Brolucizumab	0
Dexamethasone	48
Faricimab	347
Fluocinolone acetonide	**
Ranibizumab - Lucentis	10
Ranibizumab - Ongavia	0
Ranibizumab - Byooviz	0
Ranibizumab - Ximluci	0

Where the figures are less than 5, this has been denoted by \*\*. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding

this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.